Resveratrol: Why the Red Wine Molecule Disappointed in Human Trials

Scroll through any longevity feed this autumn and you will meet the same glass of red wine, the same grape-skin close-up, the same promise that one molecule can do what a good night’s sleep and a brisk walk cannot. As of late 2025, resveratrol is climbing the search charts again, pushed by creator videos, a fresh round of supplement launches and a wave of headlines asking whether the “red wine molecule” still deserves its reputation now that health agencies have stopped calling any amount of alcohol protective.

The odd thing is that the science did not just arrive. The human data on resveratrol has been sitting in the record for more than a decade, and it tells a quieter story than the marketing does. Yeast lived longer. Mice lived longer. People, so far, did not measurably change.

That gap between the petri dish and the person is what this piece is about: how resveratrol earned its fame, where the human trials went, and what a careful reader should do with a bottle that promises more than the evidence delivers.

Why is resveratrol trending again? What changed recently

Resveratrol has had several lives in the public imagination, and each revival tends to follow a shift in how we talk about alcohol. The current one is no exception. In January 2023 the WHO’s European office stated plainly that no level of alcohol consumption is safe for health, and the older idea that a nightly glass of red protects the heart has been steadily retired from mainstream guidance. When the wine loses its halo, the molecule inside it becomes the new hope, and supplement marketing follows.

Here is the timeline that matters. In 1992 French researchers described the “French paradox”: lower heart-disease death rates in France despite a diet rich in saturated fat. In 2003 a study in yeast reported that resveratrol activated a family of enzymes called sirtuins and extended the organism’s lifespan. In 2006 obese mice fed a high-fat diet plus resveratrol lived longer than their untreated peers. A pharmaceutical acquisition in 2008 signaled that industry took the idea seriously.

The turn came with human studies. A 2011 trial in 11 obese men showed modest metabolic shifts; two follow-up trials in 2012 and 2013 found nothing. In May 2014 a nine-year study of 783 older adults in Italy’s Chianti region, published in JAMA Internal Medicine, found no link between dietary resveratrol levels and death, heart disease or cancer. In 2015 a 52-week trial in Alzheimer’s disease found the compound safe but produced no cognitive benefit.

Nothing in the past two years has overturned that picture. What has changed is the volume of online enthusiasm and the decline of the wine story that resveratrol once rode. Mayo Clinic’s current summary puts it simply: the research has not shown that supplements help, and the amount in wine is too small to matter.

What does resveratrol do for the body?

Start with what it does for the plant. Resveratrol is a polyphenol, meaning a small molecule built from ring-shaped carbon structures that plants make for defense and pigment. Grapevines produce it in the skin when they are attacked by fungus or stressed by ultraviolet light; chemists call this kind of defensive compound a phytoalexin. That origin explains why cool, damp vineyards and thin-skinned red grapes tend to carry more of it, and why it turns up in the skin rather than the flesh.

In a laboratory dish, resveratrol is a busy molecule. It mops up free radicals, the unstable oxygen fragments that damage cell membranes and DNA, which is why it is labeled an antioxidant. It dampens signaling pathways that drive inflammation. It appears to nudge sirtuins, enzymes that help cells respond to low-energy conditions and repair DNA, and AMPK, an enzyme that acts as a cellular fuel gauge. Those two systems are the same ones that switch on during calorie restriction, the one intervention that reliably extends lifespan in laboratory animals. That overlap is the entire scientific case for resveratrol as an “anti-aging” compound.

The trouble is the phrase “in a laboratory dish.” Cells in culture are bathed in concentrations of pure resveratrol that no human bloodstream ever reaches. When people swallow it, most of the molecule is chemically tagged and cleared before it can act, a problem covered in detail further down.

So what does resveratrol do for the body? Honestly stated, the evidence supports this: it is safe in most healthy adults over weeks to a year, it is measurable in urine after eating grapes or drinking wine, and it produces small, inconsistent changes in blood markers that have not yet translated into fewer heart attacks, sharper memories or longer lives.

The French paradox: how a red wine question became a supplement

The story begins with a statistical puzzle rather than a molecule. In the early 1990s, epidemiologists noticed that French adults ate plenty of butter, cheese and cured meat yet died of coronary heart disease at rates well below those of Americans or Britons with similar cholesterol levels. A 1992 paper in The Lancet suggested that moderate red wine consumption might explain the gap, and the phrase “French paradox” was born on an American television news program soon after. Red wine sales in the United States jumped the following year.

Researchers then went looking for the ingredient. Alcohol itself raises HDL cholesterol and thins the blood slightly, which could account for some of the pattern. But red wine contains hundreds of polyphenols, and by the mid-1990s resveratrol had been singled out because it was easy to measure and behaved impressively in test tubes, blocking platelet clumping and protecting LDL cholesterol from oxidation.

Two things were quietly overlooked. First, the French paradox itself has thinner foundations than its fame suggests. Under-reporting of heart-disease deaths on French death certificates, a time lag between rising fat intake and heart disease, and the broader Mediterranean pattern of vegetables, olive oil and walking all offer explanations that do not require wine at all. Second, the leap from “French people drink red wine” to “a compound in red wine protects hearts” skipped every step of the evidence ladder that medicine normally demands.

Observational studies, which watch what people do and count outcomes, cannot separate the wine from the lifestyle that surrounds it. Moderate drinkers in many populations are also wealthier, more socially connected and more physically active. That confounding, meaning a hidden third factor that creates a false link, is the reason the wine-heart story has now largely collapsed under scrutiny, and why resveratrol inherited a debt it could never repay.

The hype years: yeast, mice and a pharmaceutical deal

If the French paradox lit the fuse, a 2003 paper in the journal Nature supplied the explosion. A university laboratory screening plant compounds reported that resveratrol activated a yeast enzyme called Sir2, a sirtuin, and stretched the lifespan of yeast cells by roughly 70 percent. Sirtuins were already linked to the life-extending effects of calorie restriction in worms and flies. Suddenly there was a candidate pill for the one intervention nobody wants to actually practice: eating far less for decades.

Three years later, the same group fed middle-aged mice a high-fat diet with or without resveratrol. The treated mice were still obese, yet they lived longer, had healthier livers and moved better on a rotating rod test. Newspapers ran photographs of sleek, active mice beside their sluggish littermates. A biotechnology company formed around the sirtuin concept, and in 2008 a major pharmaceutical firm bought it, betting that a purified resveratrol formulation could become a medicine for diabetes and cancer.

The retreat was rapid. In 2010 a clinical trial of that formulation in patients with multiple myeloma, a blood cancer, was halted after several participants developed kidney problems, and the company discontinued the product. That same year, an independent laboratory reported that resveratrol’s apparent activation of human SIRT1 depended on a fluorescent tag attached to the test substrate; without the tag, the effect largely vanished. Whether resveratrol activates sirtuins directly in living human tissue remains debated to this day.

The mice, meanwhile, never quite delivered either. A large 2011 federal study in normal-weight mice found no lifespan extension from resveratrol at any age tested, although some measures of health improved. The lesson from the hype years is not that the biology was fake, but that a compelling mechanism in yeast is a hypothesis, not a result, and hypotheses need to survive human trials before they belong in a capsule.

What the evidence actually says about resveratrol in humans

Medicine grades evidence on a ladder. At the top sit large randomized controlled trials, where volunteers are assigned by chance to the compound or a placebo so that lifestyle differences cancel out. Below them come observational studies, which follow people who happened to consume something. At the bottom sit laboratory mechanisms and expert opinion. Resveratrol has a crowded bottom rung and an almost empty top one.

Randomized trials do exist, but they share three limitations. They are small, typically 10 to 120 participants. They are short, usually 4 to 52 weeks. And they measure surrogate markers such as insulin sensitivity, blood pressure or inflammatory proteins rather than the outcomes patients care about: heart attacks, strokes, dementia diagnoses, deaths. A marker moving in a favorable direction over a month is a reason for more research, not a health claim.

Across those trials, the pattern is inconsistency. Some report small drops in systolic blood pressure or fasting glucose; others, designed almost identically, report none. Meta-analyses that pool them tend to conclude that any effect is modest, is more likely in people who already have type 2 diabetes or obesity, and rests on studies of low to moderate quality with a real risk of bias.

The observational evidence is more mature and more negative. The largest and best-designed study, which measured resveratrol breakdown products in urine rather than relying on questionnaires, found no relationship with death or disease over nine years.

No randomized trial has ever tested whether resveratrol extends human lifespan, prevents heart disease or lowers cancer incidence, and none is likely to, because such a trial would need tens of thousands of people followed for decades. The honest grade is this: strong for safety over the short term in healthy adults, weak and conflicting for metabolic markers, and absent for the outcomes that made it famous.

The Chianti study: dietary resveratrol and death rates

If you want a single study to anchor your opinion, choose the one conducted in the hills of Tuscany. Between 1998 and 2009, researchers followed 783 men and women aged 65 and older living in two towns in the Chianti wine region, a place where red wine is a daily companion to dinner rather than an occasional treat. Instead of asking people what they drank, the team measured resveratrol metabolites in urine at the start of the study, an objective marker of how much the body had actually taken in from food and drink.

Over nine years, 268 participants died, 174 developed cardiovascular disease and 34 were diagnosed with cancer. Those in the highest quarter of urinary resveratrol were no less likely to die than those in the lowest. They had no fewer heart attacks or strokes and no fewer cancers. Their blood levels of C-reactive protein and interleukin-6, two common inflammatory markers, were no different either. The findings were published in JAMA Internal Medicine in May 2014 and remain the largest objective test of dietary resveratrol in people.

Two caveats deserve a fair hearing. Dietary intake, even in wine country, is far below the concentrations used in supplement trials, so the study cannot rule out an effect at much higher exposures. And a single urine sample is an imperfect snapshot of years of eating habits, although the researchers checked that intake was stable in a subset.

Still, the study answers the question most people are really asking. Does the resveratrol in a Mediterranean diet explain why some populations age well? In the very population that inspired the red wine story, the answer was no. Whatever protects hearts in Tuscany, it is not measurable amounts of this one molecule, and the authors concluded that its anti-aging benefits in humans remain unproven.

Heart, metabolism and brain: the human trials that fell flat

The randomized trials are where the story turns from disappointing to instructive, because several were designed by researchers who expected success.

Metabolism came first. A 2011 crossover trial in 11 obese but otherwise healthy men, published in Cell Metabolism, reported that 30 days of resveratrol lowered energy expenditure, improved a measure of insulin sensitivity and reduced liver fat, a pattern the authors compared to mild calorie restriction. Excitement was brief. A 2012 trial in 45 non-obese postmenopausal women found no change in insulin sensitivity, blood lipids or inflammation after 12 weeks. A 2013 trial in 24 obese men, with tighter controls than the original, found no effect on blood pressure, energy use, fat storage or insulin action after four weeks.

Then came a finding that unsettled the exercise community. In 2013, Danish researchers gave 27 healthy but inactive men aged around 65 eight weeks of high-intensity training with either resveratrol or placebo. The placebo group improved their blood pressure, cholesterol and blood vessel function as expected. The resveratrol group improved less on several of those measures. Whether an antioxidant blunts the beneficial stress of exercise is still argued, but the result was the opposite of what marketing implies.

The brain trial was the most rigorous. Published in Neurology in 2015, it randomized 119 people with mild to moderate Alzheimer’s disease to resveratrol or placebo for 52 weeks. The compound crossed into spinal fluid and stabilized one amyloid biomarker, which is genuinely interesting. Memory and daily function, however, declined at the same rate in both groups. Brain volume shrank slightly more in the treated group, an unexplained observation that argues for caution. Weight loss and nausea were the main side effects.

Each of these trials was published in a respected journal. Together they explain why enthusiasm has moved from clinics to comment sections.

Why did resveratrol disappoint? The bioavailability problem

The core explanation is one word: bioavailability, meaning the fraction of a swallowed substance that reaches the bloodstream in its active form. For resveratrol, that fraction is remarkably small, and understanding why answers most of the puzzle.

Resveratrol is absorbed well from the gut, roughly 70 percent by some estimates. The problem is what happens next. Cells lining the intestine and, above all, the liver attach chemical tags to the molecule, either a glucuronide or a sulfate group, in a process called conjugation. This is the body’s standard way of making foreign compounds water-soluble so the kidneys can flush them out. The result is that free, unmodified resveratrol, the form that behaves so impressively in laboratory dishes, makes up well under one percent of what circulates, and its half-life in blood is measured in minutes rather than hours.

Consider the mismatch. Cell-culture experiments often use concentrations hundreds of times higher than anything measured in human plasma after a supplement. The mouse studies used intakes that, scaled to body size, dwarf what any diet provides and exceed what most supplement trials have used. People were, in effect, being asked to replicate a laboratory effect with a fraction of the exposure.

Manufacturers have responded with “trans-resveratrol” labels, which simply name the naturally dominant and more stable of the molecule’s two shapes, and with formulations claiming enhanced absorption. Some do raise blood levels for a time. Whether that changes a single health outcome has not been shown, and higher exposure was the setting in which kidney problems appeared in the 2010 cancer trial.

There is a second possibility worth stating plainly: the biology may not translate. Human cells, human aging and human disease differ from yeast and laboratory mice in ways no absorption trick can fix. Both explanations may be true at once.

Resveratrol benefits, claim by claim

Marketing copy for resveratrol benefits rarely distinguishes between what happened in a dish, what happened in a mouse and what happened in a person. The table below does. “Grade” reflects the strength of human evidence using the usual hierarchy: randomized trials rank highest, observational data next, laboratory mechanism lowest.

Claimed benefit	Laboratory and animal evidence	Human evidence	Grade for humans
Longer lifespan	Yeast, worms and obese mice lived longer; normal-weight mice did not	No trial exists; nine-year observational study found no link with mortality	None
Heart protection	Reduces platelet clumping and LDL oxidation in dishes	No trial on heart attacks or strokes; blood-pressure trials small and conflicting	Weak, inconsistent
Blood sugar control	Improves insulin signaling in rodents	Small trials mixed; possible modest effect in type 2 diabetes, none in healthy adults	Weak
Memory and dementia	Reduces amyloid in mouse models	52-week Alzheimer’s trial: biomarker change, no cognitive benefit	Negative
Cancer prevention	Slows tumor cells in culture	No prevention trials; one treatment trial halted for kidney harm	None
Anti-inflammatory	Consistent in cell studies	Inflammatory markers unchanged in Chianti cohort; trials mixed	Weak
Exercise performance	Improved endurance in mice	Blunted training gains in older men in one trial	Possibly unfavorable

Two patterns stand out. Every row with strong laboratory support has weak or absent human support, which is exactly what the bioavailability problem predicts. And the only rows with a clear human signal point in the wrong direction or toward no effect.

None of this means the compound is useless as a research tool. Its ability to reach spinal fluid and shift an amyloid marker is a legitimate scientific lead. But a lead is what scientists follow, not what consumers swallow.

What foods are high in resveratrol?

If the molecule interests you, the kitchen is a safer laboratory than the supplement aisle, and it comes with company: fiber, other polyphenols and the eating patterns that actually have outcome data behind them.

Grapes lead the list, specifically the skins of red and purple varieties, which is why red wine carries far more than white. Red wine ferments with the skins for days or weeks; white wine has them removed early. Grape juice made from dark grapes retains some. Fresh red grapes eaten whole deliver the skin, the fiber and none of the alcohol, a combination most clinicians would choose over any glass.

Peanuts are the surprise entry, including peanut butter, with boiled and sprouted peanuts measuring higher than roasted. Pistachios contribute a little. Among fruits, blueberries, cranberries, bilberries and mulberries contain small amounts. Cocoa powder and dark chocolate register too, which is part of why chocolate keeps appearing in wellness headlines.

Most supplements do not come from any of these. They are extracted from the root of Japanese knotweed, an invasive Asian plant that produces resveratrol in abundance, a fact rarely mentioned on labels that show a wine glass.

A sense of proportion matters more than a food ranking. Content varies enormously with grape variety, climate, processing and storage; two bottles from the same region can differ several-fold. And the amounts in even a resveratrol-rich diet fall far below those used in the human trials that failed, let alone the mouse studies that succeeded. Mayo Clinic’s plain conclusion is that a person would need to drink far more wine than is remotely safe to approach research-level intake.

Eat the grapes, the berries and the peanuts for what they are: whole foods within a pattern, such as the Mediterranean diet, that has trial evidence for lower cardiovascular events. The resveratrol inside them is a passenger, not the driver.

Is it safe to take resveratrol daily, and what are the resveratrol side effects?

For a healthy adult over the span of weeks to a year, the human trials paint a reassuring picture. Most participants tolerated resveratrol with no more complaints than the placebo groups. That safety record is the strongest evidence the compound has, and it deserves to be stated as clearly as the lack of benefit.

Resveratrol side effects, when they appear, cluster in the digestive tract. Nausea, loose stools, abdominal discomfort and bloating were the most common reports, and they became more frequent as trial intakes rose. Unintended weight loss occurred in the year-long Alzheimer’s trial, meaningful in a population where weight loss is already a concern. Headache and dizziness appear occasionally in trial listings.

Two signals warrant more respect. The 2010 trial in people with multiple myeloma was stopped after participants developed kidney injury; those patients had cancer affecting kidney function and received a concentrated formulation, so the finding may not apply to healthy adults, but it has never been fully explained. And the slightly greater loss of brain volume in the treated Alzheimer’s group remains an open question that the study authors themselves flagged.

What no one can tell you is what daily use for ten or twenty years does, because no study has looked. Supplements in the United States are regulated as a category of food, meaning manufacturers do not have to prove safety or effectiveness before sale, and independent testing has repeatedly found products whose contents do not match their labels.

Is it safe to take resveratrol daily? The measured answer is that short-term use appears low-risk for most healthy people, that the long-term answer is unknown, and that “low-risk” is a poor trade when the expected benefit is close to zero. Whether it makes sense for you depends on your medications and health history, which is a conversation for your clinician rather than a label.

Who should avoid resveratrol?

Because resveratrol is sold beside vitamins, people assume it behaves like one. Pharmacologically it does not. It is a biologically active molecule with several properties that matter in specific situations, and MedlinePlus and Cleveland Clinic both list groups who should be especially cautious.

People who bleed easily or take medicines that affect clotting come first. Resveratrol reduces the ability of platelets to clump, which in a dish looks cardioprotective and in a person on warfarin, a direct oral anticoagulant, aspirin or clopidogrel may add to bleeding risk. Nosebleeds, easy bruising or a heavier menstrual flow are the everyday signs to watch.

Anyone scheduled for surgery or a dental procedure belongs in the same category. Clinicians routinely ask patients to stop non-essential supplements ahead of an operation, and this one has a specific reason to be on that list. Tell the surgical team exactly what you take.

Resveratrol is a phytoestrogen, a plant compound that can weakly mimic or block the hormone estrogen. Cell studies show both actions. That uncertainty is why people with hormone-sensitive conditions, including a history of breast, uterine or ovarian cancer, endometriosis or uterine fibroids, are advised to avoid it unless their oncologist or gynecologist says otherwise.

The liver enzyme system called CYP3A4 breaks down roughly half of all prescription drugs, and resveratrol can inhibit it in laboratory studies. Statins, some blood-pressure medicines, immunosuppressants and certain antidepressants travel through that pathway. Anyone on a long medication list should assume an interaction is possible until a pharmacist or physician says otherwise.

Pregnancy and breastfeeding lack safety data, so the default is to skip it. The same applies to children and to people with kidney disease, given the 2010 trial signal. Never stop or adjust a prescribed medicine to make room for a supplement; the prescriber decides that.

Common myths about resveratrol

Viral health claims survive by being half true. Here are the ones circulating now, with the half that is missing.

“Red wine is heart-healthy because of its resveratrol.” The amount in a glass is tiny compared with any trial intake, and the population that drinks the most red wine in the world showed no benefit from dietary resveratrol over nine years. Meanwhile, alcohol raises the risk of several cancers, atrial fibrillation and high blood pressure. Health agencies no longer recommend starting to drink for any health reason.

“It mimics calorie restriction, so it slows aging.” It nudged the same cellular pathways in yeast and some mice. Normal-weight mice did not live longer, human trials did not reproduce the metabolic effects consistently, and whether it activates human sirtuins directly is disputed.

“It reverses aging or lengthens telomeres.” Telomeres are protective caps on chromosomes that shorten with cell division. No human trial has shown resveratrol lengthens them or reverses any validated marker of biological age.

“More is better.” Higher intakes bring more digestive side effects, were the setting for kidney injury in one trial, and blunted exercise gains in another. Dose-response in the beneficial direction has not been demonstrated in people.

“Natural means safe.” Most supplements are extracted from Japanese knotweed, not grapes, and interact with blood thinners and drug-metabolizing enzymes. Natural origin says nothing about interaction risk.

“Trans-resveratrol or high-absorption formulas fix the problem.” They may raise blood levels briefly. Not one has been shown to improve a clinical outcome.

“It failed because the trials were too small.” Partly fair; the trials were small. But small trials usually exaggerate benefits rather than hide them, and the best observational study was large and negative. The honest reading is not “unproven” but “tested and, so far, found wanting.”

When to see a doctor about resveratrol

Most people who try resveratrol will notice nothing at all, which is consistent with the trials. A short list of situations, however, should prompt a call or a visit rather than a wait-and-see approach.

Seek prompt medical attention if you develop any of these while taking it, especially if you also use blood thinners or antiplatelet medicines:

• Unusual bleeding: nosebleeds that are hard to stop, bleeding gums, blood in urine, black or tarry stools, or bruises appearing without injury
• Signs that could suggest kidney trouble: noticeably less urine, swelling of the ankles or around the eyes, or new fatigue with nausea
• Severe or persistent abdominal pain, vomiting or diarrhea lasting more than a couple of days
• Unexplained weight loss, particularly in an older adult
• An allergic reaction: hives, facial swelling, wheezing or difficulty breathing, which is an emergency
• New confusion, a severe headache or weakness on one side of the body, which could indicate bleeding and requires emergency care

Schedule a routine conversation, rather than an urgent one, if you take any prescription medicine and are considering resveratrol; if you have a hormone-sensitive condition, kidney disease or a bleeding disorder; if you are pregnant, breastfeeding or planning a pregnancy; or if you have surgery or a dental extraction coming up. Bring the bottle so the clinician or pharmacist can read the full ingredient list, since many products combine several extracts.

Two rules hold regardless of the answer you get. Never stop, skip or reduce a prescribed medicine in favor of a supplement, and never treat a supplement as a substitute for the blood-pressure, cholesterol or diabetes care your clinician has recommended. The decision about whether resveratrol fits into your health plan belongs to you and the person who knows your medical history, not to a label or a video.

Frequently asked questions

What does resveratrol do for the body?

In laboratory studies resveratrol acts as an antioxidant, calms inflammatory signaling and nudges enzymes linked to calorie restriction. In people, those effects have been hard to detect: small trials show inconsistent changes in blood sugar and blood pressure, and no trial has shown fewer heart attacks, strokes, dementia cases or deaths. The body clears most of it within minutes, which limits what it can do.

Who should avoid resveratrol?

People taking blood thinners or antiplatelet drugs, those with bleeding disorders, anyone with upcoming surgery, and people with hormone-sensitive conditions such as a history of breast or uterine cancer should avoid it unless a clinician advises otherwise. It is also not recommended during pregnancy or breastfeeding, for children, or for people with kidney disease. Anyone on several prescription medicines should check with a pharmacist first.

What foods are high in resveratrol?

Red and purple grape skins are the richest common source, which is why red wine contains more than white. Peanuts, especially boiled or sprouted, pistachios, blueberries, cranberries, mulberries, cocoa and dark chocolate contribute smaller amounts. Content varies widely with variety and processing. Even a diet rich in these foods provides far less than the amounts used in trials, so eat them for their overall nutrition rather than for this one molecule.

Is resveratrol safe daily for healthy adults?

Short-term daily use, up to about a year in trials, appeared low-risk for most healthy adults, with digestive upset the most common complaint. Long-term safety over many years has never been studied. Because supplements are not tested for safety or effectiveness before sale, and because the expected benefit in trials was close to zero, discuss it with your clinician before making it a habit.

What are the most common resveratrol side effects?

Nausea, diarrhea, abdominal discomfort and bloating were the most frequently reported side effects in human trials, and they became more common as intake increased. Unintended weight loss occurred in a year-long Alzheimer’s trial. A cancer treatment trial using a concentrated formulation was halted after kidney injury in some participants. Bleeding risk may rise in people already taking anticoagulant or antiplatelet medicines.

Does resveratrol help you live longer?

There is no human evidence that it does. Resveratrol extended lifespan in yeast and in obese mice on a high-fat diet, but not in normal-weight mice, and no trial has tested lifespan in people. The nine-year Chianti study found no link between dietary resveratrol levels and death rates in older adults. Claims that it reverses aging rest on laboratory mechanisms, not human results.

Does resveratrol lower blood pressure?

Possibly by a small amount in some groups, but the evidence is weak. Pooled analyses of small trials suggest a modest drop in systolic pressure mainly in people with type 2 diabetes or obesity, while several well-designed trials found no change. The studies were short and of mixed quality. It should never replace prescribed blood-pressure treatment; discuss any supplement with the prescribing clinician.

Is trans-resveratrol better than regular resveratrol?

Trans-resveratrol is simply the naturally dominant, more stable shape of the same molecule, and most supplements already contain it. Some formulations raise blood levels for a short time, but none has been shown to improve any health outcome. The core problem, rapid breakdown by the liver, is not solved by the label, and higher exposure has not been shown to be safer or more effective.

Can I get enough resveratrol from red wine?

No, and current guidance does not support drinking for health. A glass of red wine contains a tiny fraction of the amounts used in trials, and the population that drinks the most red wine showed no benefit from dietary resveratrol over nine years. Alcohol raises the risk of several cancers, high blood pressure and atrial fibrillation. Whole red grapes deliver the skin without the alcohol.

Does resveratrol interact with blood thinners?

It can. Resveratrol reduces platelet clumping in laboratory studies, so combining it with warfarin, direct oral anticoagulants, aspirin or clopidogrel may increase bleeding risk. It may also affect a liver enzyme that processes many medicines. Anyone taking these drugs should not start resveratrol without speaking to the prescriber or a pharmacist, and should report unusual bruising, nosebleeds or dark stools promptly.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.